Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
TP

WKN: 906517 | ISIN: IL0006290147 | Ticker: TEVA
NASDAQ
20.11.26 | 21:07
39,440 US-Dollar
+2,31 % +0,890
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart

Aktuelle News zur TEVA PHARMACEUTICAL INDUSTRIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TEVA PHARMACEUTICAL INDUSTRIES Aktie jetzt für 0€ handeln
15:26Chutes & Ladders-Teva loses R&D head as innovation pivot advances18
13:22H.C. Wainwright bestätigt Kaufempfehlung für Teva Pharm-Aktie - Kursziel 54 Dollar8
13:18H.C. Wainwright reiterates Buy on Teva Pharma stock, $54 target3
DoTeva loses R&D head Eric Hughes amid push to grow innovative medicines business23
DoTeva Announces R&D Leadership Transition As Chief Medical Officer Departs391PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals Industries (TEVA) announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, will leave the company after accepting...
► Artikel lesen
MiTeva Pharm: F&E-Chef Eric Hughes verlässt den Pharmakonzern32
MiTeva's R&D chief Eric Hughes to depart pharmaceutical company7
MiTeva Pharmaceutical Industries Ltd: Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company670Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successorTEL AVIV, Israel and PARSIPPANY, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Teva...
► Artikel lesen
MiTEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K, Current Report2
DiTeva to join Russell 1000 large-cap index26
DiGlenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM19
MoFDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder16
MoTeva gains at-home indication for Igalmi for agitation with schizophrenia3
MoTeva Pharm erzielt Vergleich im US-Rechtsstreit um Preisabsprachen bei Generika37
MoTeva Pharmaceutical Wins FDA Approval For IGALMI Sublingual Film For At-Home Use367PETAH TIKVA (dpa-AFX) - Monday, Teva Pharmaceutical Industries Limited (TEVA) announced that the U.S. Food and Drug Administration has approved IGALMI, also known as dexmedetomidine, sublingual...
► Artikel lesen
MoTeva Pharmaceutical Industries Ltd: U.S. FDA Approves IGALMI as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults429First at-home treatment provides a new option for patients and caregivers to address agitation outside of a healthcare settingApproval is supported by results of the Phase 3 SERENITY Trial, in which...
► Artikel lesen
13.11.Teva CEO 'proud' of pipeline buzz as innovative-generics hybrid rolls out 1st R&D day16
12.11.Piper Sandler raises Teva stock price target on pipeline strength51
12.11.H.C. Wainwright bekräftigt Kaufempfehlung für Teva Pharm dank Pipeline-Aussichten39
11.11.Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 20307
1 2 3 4 5 Weiter >>
303 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,2